30 results about "NK-1 Receptors" patented technology

The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT2 receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an α-adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor antagonist, a PDE4 inhibitor, an Neuropeptide Y5 Receptor Antagonists, a D4 receptor antagonist, a 5HT1A receptor antagonist, a 5HT1D receptor antagonist, a CRF antagonist, a monoamine oxidase inhibitor, a sedative-hypnotic drug, and an atypical antipsychotic.

The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.

There is provided inter alia a compound which is an NK-1 receptor antagonist for use in the treatment or prevention of CNV. There is also provided a compound which is an NK-1 antagonist for use in the treatment of chemical burns of the eye particularly alkali burns of the eye. There is also provided a pharmaceutical composition for topical administration to the eye comprising an NK-1 antagonist and an antibiotic agent.

Compositions containing one or more compounds with inhibitory effect on a 5-HT3a and / or NK-1 receptor are effective for preventing or treating idiopathic vomiting in a mammal.

Use of the non-peptide NK1 receptor antagonist, preferably Aprepitant, for the treatment of cancer in predetermined doses. The present invention also describes pharmaceutical compositions comprising said agents, alone or in combination with at least one other active principle, for the treatment of cancer

The present invention relates to trans-derivatives of formulawherein R1, R2, R3, and the dotted line are as defined herein and to pharmaceutically acceptable acid addition salts thereof.The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors) and simultaneously, they have good activity on the NK-1 receptor (dual effect). By virtue of their efficacy as SERT inhibitors, the compounds in the present invention are particularly useful for the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and / or in the treatment of anxiety.

The invention provides a compound which exhibits satisfactory peroral absorbability and excellent antagonistic activity against NK-1 receptor or NK-2 receptor. The compound is a benzylamine derivative represented by formula (1) or a salt thereof.

The invention provides a compound which exhibits satisfactory peroral absorbability and excellent antagonistic activity against NK-1 receptor or NK-2 receptor. The compound is a benzylamine derivative represented by formula (1) or a salt thereof

The present invention relates to compositions containing plant materials or extracts with inhibitory effect on a 5-HT3a and / or NK-1 receptor for preventing or treating idiopathic vomiting.

The present invention provides a substance P polypeptide probe that specifically recognizes neurokinin-1 receptor protein. The substance P polypeptide probe is a polypeptide dimer or a polypeptide polymer, and its monomer consists of a substance P amino acid sequence MLGFFQQPKPR, A bifunctional chelating group, a fluorescent group and a terpyridine group are connected through lysine. The polypeptide probe is a new type of polypeptide dimer and polypeptide polymer used to prepare various tumor diagnostic functions. The polypeptide dimer and polypeptide polymer label metal Gd3+ to the polypeptide through a bifunctional chelating group Molecularly, the labeled Substance P polypeptide probe in vivo specifically binds to the NK-1 receptor protein and concentrates on the tumor site, and uses magnetic imaging and optical imaging techniques to detect the neurokinin-1 receptor protein to improve detection sensitivity sex.

Provided herein are conjugates including a targeting vehicle coupled to an agent. The targeting vehicle includes a tachykinin receptor ligand and a reactive moiety. Conjugates including a tachykinin receptor ligand attached to an antibody or fragment thereof that is specific for an intracellular target are also provided. Also provided are methods of delivering agents to cells expressing tachykinin receptors, methods of delivering antibodies or fragments thereof to an intracellular extra-endosomal target, and methods of arresting cell growth or introducing cell death of a cancer cell.

The invention relates to a targeted NK1 receptor antagonist and its application in the treatment of nausea and vomiting caused by chemotherapy, and belongs to the technical field of drugs for adjuvant chemotherapy of tumors. The present invention provides compounds represented by the following formula I, their racemates, stereoisomers, tautomers, isotope labels, nitrogen oxides or pharmaceutically acceptable salts thereof: the present invention also provides the compounds The preparation method, pharmaceutical composition and use of the invention.

An NK1 receptor antagonist composition of the present invention uses maltooligosaccharide having an NK1 receptor antagonistic activity as an active ingredient. A suitable amount of the maltooligosaccharide to be blended in the NK1 receptor antagonist composition of the present invention is 0.000001 to 70% by weight. The NK1 receptor antagonist composition of the present invention is prepared for use into various forms of external agents, internal medicines, foods and beverages by blending various materials as the ingredients other than the active ingredient. The NK1 receptor antagonist composition of the present invention has high safety for being used for pharmaceuticals and has satisfactory therapeutic effects.

Disclosed herein are methods of treating an individual who is experiencing or is at risk of experiencing an undesirable consequence of opioid use, and of treating an individual who is experiencing oris at risk of experiencing desire for opioid, and uses of an NK1 receptor antagonist Chudepitant in treating the individual.